Skip to main content
SpringerLink
Log in

Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

The recently discovered fourth member of the opioid receptor family, the nociceptin receptor (NOP) and its endogenous ligand, the heptadecaptide nociceptin, are involved in several central nervous system pathways, such as nociception, reward, tolerance, and feeding. The discovery of small-molecule ligands for NOP is being actively pursued for several therapeutic applications. This review presents a brief overview of the several recently reported NOP ligands, classified as NOP agonists and antagonists, with an emphasis on the analysis of the structural features that may be important for modulating the agonist/antagonist profile (intrinsic activity) of these ligands. Structure-activity relationships in our own series of dihydroindolinone-based NOP ligands and those of the various reported ligands indicate that the lipophilic substituent on the common basic nitrogen present in all NOP ligands plays a role in determining the agonist/antagonist profile of the NOP ligand. This analysis provides a basis for the rational drug design of NOP ligands of desired intrinsic activity and provides a framework for developing pharmacophore models for high affinity binding and intrinsic activity at the NOP receptor. Since NOP agonists and antagonists both have therapeutic value, rational approaches for obtaining both within a high-affinity binding class of compounds are very useful for designing potent and selective NOP ligands with the desired profile of intrinsic efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bigoni R, Giuliani S, Calo' G, et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.Naunyn Schmiedebergs Arch Pharmacol. 1999;359:160–167.

    Article  PubMed  CAS  Google Scholar 

  2. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor.Peptides. 2000;21:907–917.

    Article  PubMed  CAS  Google Scholar 

  3. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.Pharmacol Rev. 2001;53:381–415.

    PubMed  CAS  Google Scholar 

  4. Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D. Pharmacology of noniceptin and its receptor: a novel therapeutic target.Br J Pharmacol. 2000;129:1261–1283.

    Article  PubMed  Google Scholar 

  5. Zaveri N, Polgar WE, Olsen CM, et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.Eur J Pharmacol. 2001;428:29–36.

    Article  PubMed  CAS  Google Scholar 

  6. Lutfy K, Eitan S, Bryant C, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.J Neurosci. 2003;23: 10331–10337.

    PubMed  CAS  Google Scholar 

  7. Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.Life Sci. 2003;73:663–678.

    Article  PubMed  CAS  Google Scholar 

  8. Ronzoni S, Peretto I, Giardina GA. Lead generation and lead optimization approaches in the discovery of selective, nonpeptide ORL-1 receptor agonists and antagonists.Expert Opin Ther Patents. 2001;11:525–546.

    Article  CAS  Google Scholar 

  9. Zaveri NT, Jiang F, Olsen CM, et al. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.J Med Chem. 2004;47:2973–2976.

    Article  PubMed  CAS  Google Scholar 

  10. Wichmann J, Adam G, Rover S, et al. Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one, a potent and selective orphanin FO (OFQ) receptor agonist with anxiolytic-like properties.Eur J Med Chem. 2000;35:839–851.

    Article  PubMed  CAS  Google Scholar 

  11. Rover S, Adam G, Cesura AM, et al. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.J Med Chem. 2000;43:1329–1338.

    Article  PubMed  CAS  Google Scholar 

  12. Rover S, Wichmann J, Jenck F, Adam G, Cesura AM. ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones.Bioorg Med Chem Lett. 2000;10:831–834.

    Article  PubMed  CAS  Google Scholar 

  13. Ito F, Ohashi Y, inventor. Pfizer, Inc., assignee. 1,3,8-Triazaspiro[4,5]decanone compounds as ORL1-receptor agonists. European patent application, European patent 0 997 464 A1. July 10, 1999.

  14. Kolczewski S, Adam G, Cesura AM, et al. Novel hexahydrospiro [piperidine-4,1′[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptors agonists.J Med Chem. 2003;46:255–264.

    Article  PubMed  CAS  Google Scholar 

  15. Tulshian D, Ho GD, Silverman LS, et al, inventor. Schering Corporation, assignee. High affinity ligands for nociceptin receptor ORL-1. US patent 6 262 066 B1. July 17, 2001.

  16. Chen Z, Miller WS, Shan S, Valenzano KJ. Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor.Bioorg Med Chem Lett. 2003;13:3247–3252.

    Article  PubMed  CAS  Google Scholar 

  17. Kawamoto H, Ozaki S, Itoh Y, et al. Discovery of the first potent and selective small molecular opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).J Med Chem. 1999;42:5061–5063.

    Article  PubMed  CAS  Google Scholar 

  18. Ozaki S, Kawamoto H, Ito Y, Hayashi K, Hirano K, Iwasawa Y, inventor. Banyu Pharmaceutical Co., assignee. New 2-oxoimidazole derivatives. US patent 6 258 825. July 10, 2001.

  19. Kawamoto H, Ozaki S, Ito, Y, Iwazawa Z, inventor. Banyu Pharmaceutical Co, assignee. 4-Oxoimidazolidine-5-spiro-nitrogen-containing heterocyclic compound. Japan patent application 20001169476. June 20, 2000.

  20. Zaratin PF, Petrone G, Sbacchi M, et al. Modification of nociceptin and morphine tolerance by the selective ORL-1 antagonist (−)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).J Pharmacol Exp Ther. 2004;308:454–461.

    Article  PubMed  CAS  Google Scholar 

  21. Shinkai H, Ito T, Iida T, Kitao Y, Yamada H, Uchida I. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.J med Chem. 2000;43:4667–4677.

    Article  PubMed  CAS  Google Scholar 

  22. Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K. Pharmacological profiles of a novel opioid receptor-likel (ORL1) receptor antagonist, JTC-801.Br J Pharmacol. 2002;135:323–332.

    Article  PubMed  CAS  Google Scholar 

  23. Muratani T, Minami T, Enomoto U, et al. Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride. In:J Pharmacol Exp Ther. vol. 303. 2002:424–430.

  24. Mabuchi T, Matsumura S, Okuda-Ashitaka E, et al. Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production.Eur J Neurosci. 2003;17:1384–1392.

    Article  PubMed  Google Scholar 

  25. Mouledous L, Topham CM, Moisand C, Mollereau C, Meunier JC. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain.Mol Pharmacol. 2000,57:495–502.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biosciences Division, SRI International, 333 Ravenswood Ave, 94025, Menlo Park, CA

    Nurulain Zaveri (Drug Discovery Program Director), Faming Jiang, Cris Olsen, Willma Polgar & Lawrence Toll

Authors
  1. Nurulain Zaveri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faming Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cris Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Willma Polgar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lawrence Toll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nurulain Zaveri.

Additional information

Published: October 5, 2005

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zaveri, N., Jiang, F., Olsen, C. et al. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP. AAPS J 7, 34 (2005). https://doi.org/10.1208/aapsj070234

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/aapsj070234

Keywords

Search

Navigation